CL2016000787A1 - Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih). - Google Patents

Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).

Info

Publication number
CL2016000787A1
CL2016000787A1 CL2016000787A CL2016000787A CL2016000787A1 CL 2016000787 A1 CL2016000787 A1 CL 2016000787A1 CL 2016000787 A CL2016000787 A CL 2016000787A CL 2016000787 A CL2016000787 A CL 2016000787A CL 2016000787 A1 CL2016000787 A1 CL 2016000787A1
Authority
CL
Chile
Prior art keywords
composition
cobicistat
tablet
atazanavir
hiv
Prior art date
Application number
CL2016000787A
Other languages
English (en)
Inventor
Otilia May Yue Koo
Faranak Nikfar
Jing Tao
Niranjan Kumar Kottala
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of CL2016000787A1 publication Critical patent/CL2016000787A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud describe a una composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat en forma de cobicistat en dióxido de silicio; un procedimiento de preparación de la composición en forma de comprimido; y su uso para preparar un medicamento para tratar la infección por el virus de inmunodeficiencia humana (VIH).
CL2016000787A 2013-10-07 2016-04-05 Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih). CL2016000787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07

Publications (1)

Publication Number Publication Date
CL2016000787A1 true CL2016000787A1 (es) 2016-11-25

Family

ID=51743576

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000787A CL2016000787A1 (es) 2013-10-07 2016-04-05 Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).

Country Status (28)

Country Link
US (2) US20160038502A1 (es)
EP (2) EP3054926B1 (es)
JP (2) JP6574415B2 (es)
KR (1) KR102286386B1 (es)
CN (1) CN106029058A (es)
AU (1) AU2014332200B2 (es)
BR (1) BR112016007526A8 (es)
CA (1) CA2926650A1 (es)
CL (1) CL2016000787A1 (es)
CY (1) CY1121105T1 (es)
DK (2) DK3421033T3 (es)
EA (1) EA031172B1 (es)
ES (2) ES2927484T3 (es)
HR (2) HRP20221126T1 (es)
HU (1) HUE059757T2 (es)
IL (1) IL244881B (es)
LT (2) LT3054926T (es)
MX (1) MX368268B (es)
MY (1) MY178960A (es)
PE (1) PE20160596A1 (es)
PL (2) PL3054926T3 (es)
PT (2) PT3054926T (es)
RS (2) RS57882B1 (es)
SA (1) SA516370891B1 (es)
SG (1) SG11201602501VA (es)
SI (2) SI3054926T1 (es)
SM (2) SMT201800507T1 (es)
WO (1) WO2015054133A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
ES2952878T3 (es) * 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) * 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
WO2008037082A1 (en) * 2006-09-25 2008-04-03 Archer-Daniels-Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2009084086A1 (ja) * 2007-12-27 2009-07-09 Fujitsu Limited 通信システム，回線提供装置および通信方法
AU2009296734B2 (en) * 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
CN102917695A (zh) * 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
US20160038502A1 (en) * 2013-10-07 2016-02-11 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat

Also Published As

Publication number Publication date
EP3421033A1 (en) 2019-01-02
SI3421033T1 (sl) 2022-11-30
BR112016007526A8 (pt) 2020-03-03
PL3054926T3 (pl) 2018-12-31
DK3421033T3 (da) 2022-10-10
EP3421033B1 (en) 2022-07-27
PT3421033T (pt) 2022-09-23
EA031172B1 (ru) 2018-11-30
EP3054926B1 (en) 2018-07-25
MY178960A (en) 2020-10-26
SI3054926T1 (sl) 2018-10-30
LT3421033T (lt) 2022-11-10
ES2927484T3 (es) 2022-11-07
US20190358240A1 (en) 2019-11-28
IL244881B (en) 2021-12-01
DK3054926T3 (en) 2018-10-29
EP3054926A1 (en) 2016-08-17
HRP20181582T1 (hr) 2018-11-30
US20160038502A1 (en) 2016-02-11
SMT202200373T1 (it) 2022-11-18
MX2016004078A (es) 2016-06-06
HUE059757T2 (hu) 2023-01-28
LT3054926T (lt) 2018-11-12
RS63570B1 (sr) 2022-10-31
SA516370891B1 (ar) 2018-08-08
CN106029058A (zh) 2016-10-12
KR102286386B1 (ko) 2021-08-05
JP6574415B2 (ja) 2019-09-11
BR112016007526A2 (pt) 2017-08-01
EA201690594A1 (ru) 2016-09-30
AU2014332200A1 (en) 2016-05-19
PE20160596A1 (es) 2016-06-15
CA2926650A1 (en) 2015-04-16
SG11201602501VA (en) 2016-04-28
PT3054926T (pt) 2018-10-26
HRP20221126T1 (hr) 2022-11-25
WO2015054133A1 (en) 2015-04-16
IL244881A0 (en) 2016-05-31
MX368268B (es) 2019-09-26
JP2016532649A (ja) 2016-10-20
PL3421033T3 (pl) 2022-10-03
RS57882B1 (sr) 2019-01-31
SMT201800507T1 (it) 2018-11-09
JP2019011334A (ja) 2019-01-24
ES2693580T3 (es) 2018-12-12
CY1121105T1 (el) 2019-12-11
AU2014332200B2 (en) 2018-10-04
KR20160060764A (ko) 2016-05-30

Similar Documents

Publication Publication Date Title
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
CR20150326A (es) Inhibidores de autotaxina
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2015016627A (es) Vacuna para la malaria.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH